Subcutaneous Pharmacokinetics of Belatacept

Pharmacokinetics, Safety and Immunogenicity of Single Doses of Belatacept Administered Subcutaneously to Healthy Subjects

Pharmacokinetics, Bioavailability, Safety and Immunogenicity of Single Doses of Belatacept Administered Subcutaneously to Healthy Subjects

Inclusion Criteria:

• Men and women ages 18 to 65 years old
• Subjects must weigh less than or equal to 100 kg

Exclusion Criteria:

• Inability to tolerate injections or IV infusions
• autoimmune disorders
• TB
• herpes
• HCV
• HBV
• HIV
• bacterial or viral infection
• history of cancer